Ignite Creation Date:
2025-12-26 @ 1:16 PM
Ignite Modification Date:
2025-12-29 @ 4:31 PM
Study NCT ID:
NCT01337206
Status:
COMPLETED
Last Update Posted:
2015-02-06
First Post:
2011-04-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SX ELLA Esophageal Degradable BD Stent System
Sponsor:
Cook Group Incorporated
Organization:
Study Overview
Official Title:
Evaluation of the Effectiveness of the SX ELLA Esophageal Degradable BD (BD Stent) Stent System
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DESTINY
Brief Summary:
The SX-ELLA Stent Esophageal Degradable BD (BD Stent) is designed for dilation of benign esophageal lesions, namely: (1) stenosis (peptic, anastomotic or caustic) refractory to standard therapy, (2) achalasia refractory to standard therapy.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: